Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | HAO2 | Q9NYQ3 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 3/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL6080245 | 0.93 | KDM4E (0.37) | DHODHRXRANR4A2PDE4BPDE4D | |
| SCHEMBL6079660 | 0.82 | DHODH (0.37) | DUSP3HAO2DHFRDHODHKDM4E | |
| SCHEMBL6079834 | 0.79 | P2RX3 (0.44) | — | |
| SCHEMBL6080544 | 0.76 | KDM4E (0.34) | DHODHPDE4BPDE4DKDM4EPOLB | |
| SCHEMBL6079395 | 0.75 | PARP1 (0.38) | DHODHKDM4E | |
| Benzene SCHEMBL6080781 | 0.75 | PARP1 (0.38) | DHODHKDM4E | |
| SCHEMBL6080476 | 0.74 | DHODH (0.34) | DHODHKDM4E | |
| SCHEMBL6080559 | 0.71 | MCL1 (0.38) | DHODH | |
| SCHEMBL6081190 | 0.70 | DHFR (0.39) | DHFRKDM4ECCR6 | |
| SCHEMBL6080473 | 0.69 | PIN1 (0.38) | PDE4BPDE4DKDM4EPOLBPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | DUSP3 3566/4885HAO2 4233/4885DHFR 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.